The Cambridge company began with one postdoc’s bad antibody problem. Twenty-eight years later, its real product is not merely a vial - it is the confidence that a costly experiment will not have to be run twice.
Pando Bioscience is an AI-driven synthetic biology company that engineers better enzymes for the pharmaceutical and diagnostics industries. It pairs a generative-AI design model with an ultra-high-throughput 'one-pot' screening platform that tests roughly 1,000 times more enzyme variants - about 75% faster and 80% cheaper than conventional methods - compressing the design-build-test-learn cycle to about one month. Founded in 2022 by former Ginkgo Bioworks scientists Will Cao and Yang Wang, Pando both improves customers' enzymes and builds its own proprietary enzyme assets, such as the Saiyan-Phi29 polymerase.
Paragon Genomics is a Fremont, California biotechnology company that makes it faster and cheaper to read the parts of a genome that actually matter. Its patented CleanPlex amplicon sequencing technology turns tiny or degraded DNA and RNA samples into sequencing-ready libraries in a few hours, powering targeted next-generation sequencing for cancer research, infectious-disease surveillance, inherited-disease testing and agricultural genomics. Founded in 2015 and backed by an $8M Series A, the company sells both ready-to-use and custom NGS panels to more than 300 labs worldwide.